Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1844199

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1844199

Neurovascular Intervention Devices Market by Product Type, Indication, End User, Procedure Type - Global Forecast 2025-2032

PUBLISHED:
PAGES: 193 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (2-5 User License)
USD 4249
PDF, Excel & 1 Year Online Access (Site License)
USD 5759
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Neurovascular Intervention Devices Market is projected to grow by USD 7.14 billion at a CAGR of 6.69% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.25 billion
Estimated Year [2025] USD 4.53 billion
Forecast Year [2032] USD 7.14 billion
CAGR (%) 6.69%

A clear and engaging orientation to recent neurovascular device innovations, clinical adoption drivers, and strategic considerations shaping stakeholder decisions

The landscape of neurovascular intervention devices is evolving rapidly, driven by convergent advances in device engineering, imaging, and acute care pathways. Over the last several years clinicians and device developers have moved from incremental improvements toward platform-level innovations that change how complex cerebrovascular diseases are diagnosed, treated, and managed. These shifts have heightened the imperative for stakeholders to understand not only product-level differentiators but also how procedural workflows, reimbursement dynamics, and care setting preferences interact to shape adoption and outcomes.

This executive summary synthesizes cross-cutting trends and strategic imperatives for manufacturers, clinical leaders, and investors who operate in or adjacent to the neurovascular domain. It situates technology progress-such as enhancements in flow diversion materials and thrombectomy device deliverability-alongside evolving procedural approaches and payer considerations. By clarifying the drivers of clinical adoption and the competitive tensions across product categories and indications, the narrative aims to equip decision-makers with a clear, actionable perspective that supports prioritization of R&D, go-to-market investments, and partnership strategies.

Throughout the following sections, the analysis maintains an emphasis on practical implications, balancing technical detail with commercial context to facilitate rapid translation of insight into operational planning and resource allocation.

How material science breakthroughs, imaging integration, and evolving care delivery models are reshaping device adoption and clinical pathways in neurovascular care

The neurovascular device landscape is undergoing transformative shifts that extend beyond device-level improvements to encompass procedural paradigms and care delivery models. Material science breakthroughs and refined designs have increased device efficacy and safety profiles, enabling clinicians to tackle previously untreatable anatomies and complex lesion morphologies. Simultaneously, enhanced imaging integration and navigation systems have reduced procedural times and improved the precision of device deployment, which in turn has broadened the pool of eligible patients and increased clinician confidence in advanced interventions.

As procedural success rates and operator familiarity grow, new pathways for care are emerging, including expanded utilization in ambulatory surgical settings and the creation of multidisciplinary stroke networks that streamline triage and treatment. These systemic shifts are reinforced by an emphasis on value-based care and outcomes reporting, which incentivize devices and procedural approaches that demonstrably reduce complications, rehospitalizations, and long-term disability. Consequently, companies that align product development with measurable clinical outcomes and streamlined workflows will be better positioned to gain traction.

Finally, collaboration models between device manufacturers and clinical centers are evolving to accelerate real-world evidence generation and iterative device refinement. Strategic partnerships that integrate post-market surveillance, registries, and payer engagement are becoming essential components of commercialization strategies, reshaping how innovations migrate from regulatory approval to routine clinical practice.

Assessing the practical repercussions of new tariff policies on supply chains, procurement decisions, and commercialization strategies across neurovascular device stakeholders

The introduction of tariffs in 2025 for certain medical device components and finished goods has introduced an additional layer of procurement and supply chain complexity for neurovascular device stakeholders. Manufacturers with global manufacturing footprints have been prompted to reassess sourcing strategies and cost structures to mitigate margin erosion and maintain price competitiveness. In turn, procurement teams within health systems and group purchasing organizations are weighing the trade-offs between short-term cost increases and long-term clinical value, particularly for devices that deliver demonstrable reductions in procedure time, complication rates, or subsequent care requirements.

Immediate responses have included a re-evaluation of supplier contracts, increased emphasis on nearshoring or regional manufacturing partnerships, and selective repricing of products where contractual flexibility and payer dynamics permit. In some cases, developers have accelerated investments in design simplification and component consolidation to reduce exposure to tariffed inputs. Meanwhile, clinicians and hospital administrators are focused on preserving procedural continuity and access to best-in-class devices; therefore, strategic communication of health-economic benefits and comparative clinical outcomes has become more critical to offset procurement pressures.

Looking ahead, sustained tariff-related cost pressures will favor organizations that can demonstrate total cost of care benefits, secure resilient supply chains, and adapt commercial strategies to evolving procurement frameworks. Transparent cost-effectiveness evidence and flexible distribution agreements will be pivotal in maintaining market access under shifting trade conditions.

Integrated segmentation insights that reveal how product types, clinical indications, care settings, and procedure types jointly determine adoption dynamics and commercial priorities

The market segmentation framework yields specific insights when product, indication, end user, and procedure perspectives are integrated. Based on product type, device categories such as embolic agents, flow diverters, microcatheters, neurovascular coils, stents, and thrombectomy devices each present distinct clinical and commercial dynamics. Within embolic agents, the distinctions between liquid embolics and particulate embolics influence procedural technique, storage and handling considerations, and clinical use cases. Flow diverters show differentiated value propositions across devices such as the Pipeline Embolization Device and the Surpass Flow Diverter, where differences in deliverability, radial force, and endothelialization profiles affect clinician preference. Microcatheter coatings, whether hydrophilic or polymer-based, change the tactile and navigational characteristics that operators rely upon, while coil technologies that are detachable versus pushable define different trade-offs in deployment control and repositionability. Stent platforms that are balloon-mounted versus self-expanding present distinct lesion preparation and deployment workflows, and thrombectomy strategies split between aspiration devices and stent retrievers, each with specific procedural success patterns that inform institutional purchasing decisions.

When viewed through the lens of indication, aneurysm treatment pathways, arteriovenous malformation interventions, and acute ischemic stroke care place divergent demands on device performance, inventory management, and procedural team composition. End user segmentation-ambulatory centers, clinics, and hospitals-further modulates adoption timelines and procurement behaviors, with ambulatory centers often prioritizing streamlined, high-throughput solutions and hospitals emphasizing versatility and comprehensive inventory to support complex cases. Finally, procedure type segmentation across embolization, flow diversion, and thrombectomy highlights how procedural volume, operator expertise, and case complexity interact to determine device mix and consumable usage.

Taken together, these segmentation lenses underscore the importance of tailoring product design, training programs, and commercial messaging to the nuanced needs of each clinical and operational context, ensuring that innovations are positioned to overcome adoption barriers and deliver measurable clinical impact.

Comparative regional dynamics revealing how regulatory environments, payer structures, and clinical networks drive differentiated adoption and commercialization pathways

Regional dynamics in neurovascular interventions reflect differences in regulatory frameworks, health system architectures, and patterns of clinical practice. In the Americas, advanced stroke systems and robust tertiary care networks have facilitated rapid uptake of endovascular solutions, with a pronounced emphasis on integrating pre-hospital triage and inter-hospital transfer protocols to maximize timely intervention. This region often serves as an early adopter environment for novel devices when backed by strong clinical evidence and health-economic justification, and payers increasingly scrutinize comparative outcomes as part of coverage decisions.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization in certain markets coexists with variable access and reimbursement policies in others. Clinician networks and center-of-excellence models drive adoption in major urban centers, while translation to broader populations depends on local procurement practices and reimbursement alignment. In some EMEA markets, constrained capital budgets emphasize value-based purchasing and long-term cost-of-care arguments, creating opportunities for devices that demonstrably reduce overall treatment burden.

Asia-Pacific exhibits rapid adoption in high-volume centers alongside growing domestic device development ecosystems. Health systems across the region are investing in stroke infrastructure and advanced neurointerventional training, which supports scaling of both established and newer device categories. However, fragmented regulatory pathways and diverse payer arrangements require nuanced market entry strategies, including local partnerships and region-specific clinical evidence generation. Across all regions, supply chain resilience, regulatory readiness, and evidence tailored to local practice patterns are decisive factors in successful market penetration.

Competitive and collaborative dynamics that determine market leadership through clinical evidence, manufacturing agility, and strategic alignment with health system priorities

Competitive dynamics in neurovascular interventions are shaped by a mix of established device innovators, emerging specialized firms, and vertically integrated healthcare technology companies. Leading organizations typically invest heavily in iterative device refinement, robust clinical trial programs, and broad training initiatives that reduce operator learning curves and accelerate institutional adoption. Meanwhile, smaller, agile firms frequently introduce differentiated materials or delivery mechanisms that challenge incumbents and catalyze category expansion, particularly in niche anatomies or procedural workflows where incremental improvements yield outsized clinical benefit.

Partnerships between device developers and clinical centers of excellence are a common strategic approach to generate real-world evidence and optimize device iterations based on procedural feedback. These collaborative models support faster clinical adoption by building local expertise and producing the outcome data required for payer engagement. Additionally, companies that align their commercial strategies with health system priorities-such as reducing length of stay, decreasing complication rates, or enabling same-day procedures-find it easier to secure formulary inclusion and favorable procurement terms.

Intellectual property strength, manufacturing scalability, and supply chain diversification remain decisive competitive levers. Organizations that demonstrate sustained investment in post-market surveillance, education programs, and integrated clinical support are better positioned to retain market share and expand into adjacent indications and geographies. The most resilient players combine technical excellence with operational fluency across regulatory, reimbursement, and clinical adoption channels.

Actionable strategic and operational recommendations for aligning product design, evidence generation, and commercial execution to secure sustainable adoption and value

Industry leaders should adopt a coordinated strategy that aligns product development, evidence generation, and commercial execution to accelerate adoption and defend market position. Prioritizing design choices that optimize deliverability and procedural efficiency will resonate with clinicians focused on reducing procedure time and improving safety outcomes. Concurrently, investing in robust real-world evidence programs and health-economic analyses will be critical to persuade procurement committees and payers that device selection yields measurable reductions in total cost of care.

Operationally, companies should pursue supply chain resilience by diversifying sourcing, exploring regional manufacturing partnerships, and simplifying bill-of-materials where feasible to mitigate exposure to trade fluctuations. Commercially, tailoring training and support models to end user segmentation-differentiating approaches for ambulatory centers, clinics, and hospitals-will help accelerate adoption while maintaining service quality. Strategic partnerships with leading clinical centers to develop best-practice protocols and case libraries will shorten learning curves and build trust among broader clinician cohorts.

Finally, leadership teams must maintain flexibility in pricing and contracting models to accommodate varied reimbursement environments and procurement processes. Value-based contracting, risk-sharing arrangements, and bundled payment models should be explored where outcomes data support such structures. By integrating clinical, operational, and commercial priorities into a single coherent plan, organizations can convert innovation into sustainable clinical and financial value.

A transparent and multi-method research approach that combines expert interviews, literature synthesis, and scenario testing to ensure robust, actionable insights

The research methodology underpinning this analysis integrates multiple qualitative and quantitative approaches to ensure rigour and relevance. Primary inputs include structured interviews with clinical experts, procurement leaders, and industry executives, which provide contextual understanding of procedural workflows, adoption drivers, and purchasing decision criteria. These conversations are triangulated with a review of peer-reviewed clinical literature, regulatory filings, and conference proceedings to validate performance claims and identify emerging clinical consensus.

Complementary secondary research examines device design trends, manufacturing considerations, and supply chain dynamics, with attention to changes in trade policy and regional regulatory developments. The methodology also incorporates an assessment of reimbursement and health-economic literature to frame adoption incentives and payer perspectives. Data synthesis emphasizes cross-validation across sources and a clear delineation between evidence-based findings and expert opinion, with transparency about the level of confidence for key conclusions.

Where appropriate, scenario analysis is used to explore the implications of policy shifts, supply chain disruptions, and differential adoption rates across care settings. Throughout, the approach prioritizes actionable insight, linking technical device characteristics to operational and commercial outcomes that matter to clinicians, hospital executives, and investors.

Concluding synthesis that connects device innovation, evidence strategy, and operational resilience as the keys to sustainable impact and competitive advantage

In summary, the neurovascular intervention space is transitioning from incremental refinements to transformative innovations that reshape clinical pathways, procurement behaviors, and competitive dynamics. Advances in device design and procedural technology are expanding treatment possibilities and improving outcomes, but successful commercialization increasingly requires integrated strategies that align clinical evidence, supply chain resilience, and payer engagement. The 2025 tariff landscape has amplified the need for nimble sourcing strategies and stronger articulation of total cost of care benefits to maintain market access and clinician adoption.

Segmentation-specific approaches-attuned to product nuances, indication requirements, end-user preferences, and procedural contexts-are essential to prioritize investments and craft persuasive value propositions. Regionally differentiated strategies are equally important, as regulatory, reimbursement, and care delivery frameworks materially influence adoption timing and scale. Companies that combine technical excellence with rigorous evidence programs, adaptable commercial models, and resilient operations will be best positioned to lead.

Ultimately, the path from innovation to standard of care depends on deliberate execution across clinical, commercial, and operational domains. Stakeholders who act proactively to align these elements will capture the greatest value and contribute meaningfully to improved patient outcomes in neurovascular care.

Product Code: MRR-ED54C46E8FA1

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of flow diversion devices for complex intracranial aneurysm treatment improving long-term occlusion rates
  • 5.2. Advances in biodegradable embolic materials reducing risk of chronic inflammation and aiding vessel remodeling
  • 5.3. Integration of real-time robotic-assisted neurovascular navigation systems enhancing procedural precision and safety
  • 5.4. Development of next-generation thin-walled stents for improved vessel conformability and reduced thrombogenicity
  • 5.5. Implementation of artificial intelligence-driven imaging analytics for optimized endovascular procedure planning
  • 5.6. Rise in demand for microcatheters with improved torque control to navigate tortuous cerebral vasculature effectively
  • 5.7. Expansion of hybrid operating room suites combining CT angiography and fluoroscopy to streamline neurointerventions
  • 5.8. Growth in minimally invasive liquid embolic agents enabling targeted vascular occlusion with lower risk profiles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurovascular Intervention Devices Market, by Product Type

  • 8.1. Embolic Agents
    • 8.1.1. Liquid Embolics
    • 8.1.2. Particulate Embolics
  • 8.2. Flow Diverters
    • 8.2.1. Pipeline Embolization Device
    • 8.2.2. Surpass Flow Diverter
  • 8.3. Microcatheters
    • 8.3.1. Hydrophilic Coated
    • 8.3.2. Polymer Coated
  • 8.4. Neurovascular Coils
    • 8.4.1. Detachable Coils
    • 8.4.2. Pushable Coils
  • 8.5. Stents
    • 8.5.1. Balloon Mounted
    • 8.5.2. Self Expanding
  • 8.6. Thrombectomy Devices
    • 8.6.1. Aspiration Devices
    • 8.6.2. Stent Retriever

9. Neurovascular Intervention Devices Market, by Indication

  • 9.1. Aneurysm
  • 9.2. Arteriovenous Malformation
  • 9.3. Stroke

10. Neurovascular Intervention Devices Market, by End User

  • 10.1. Ambulatory Centers
  • 10.2. Clinics
  • 10.3. Hospitals

11. Neurovascular Intervention Devices Market, by Procedure Type

  • 11.1. Embolization
  • 11.2. Flow Diversion
  • 11.3. Thrombectomy

12. Neurovascular Intervention Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neurovascular Intervention Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neurovascular Intervention Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Stryker Corporation
    • 15.3.2. Medtronic plc
    • 15.3.3. Johnson & Johnson
    • 15.3.4. Penumbra, Inc.
    • 15.3.5. Boston Scientific Corporation
    • 15.3.6. Terumo Corporation
    • 15.3.7. Becton, Dickinson and Company
    • 15.3.8. MicroPort Scientific Corporation
    • 15.3.9. MicroVention, Inc.
    • 15.3.10. Kaneka Corporation
Product Code: MRR-ED54C46E8FA1

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NEUROVASCULAR INTERVENTION DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NEUROVASCULAR INTERVENTION DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEUROVASCULAR INTERVENTION DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!